ClinConnect ClinConnect Logo
Search / Trial NCT01186744

A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Launched by PFIZER · Aug 20, 2010

Trial Information

Current as of June 13, 2025

Completed

Keywords

Opt Retreatment Opt Chronic Moderate Severe Treatment Safety Treatment Withdrawal Retreatment Retreatment Withdrawal Cp 690,550 Psoriasis Vulgaris Plaque Psoriasis Tofacitinib Xeljanz Nail Psoriasis Jak Inhibitor Oral Treatment Pruritus Itch Dlqi Rebound Intermittent Retreat

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 18 years or older with diagnosis of plaque-type psoriasis (psoriasis vulgaris) for at least 12 months prior to first dose of study drug;
  • Psoriasis Area and Severity Index (PASI) score of 12 or greater, AND Physician's Global Assessment (PGA) score of 3 (moderate) or 4 (severe); Psoriasis covering at least 10% of body surface area;
  • No evidence of active or latent or inadequately treated infection with Tuberculosis or other serious infections.
  • Exclusion Criteria:
  • Non-plaque or drug induced forms of psoriasis;
  • Cannot discontinue current oral, injectable or topical therapy for psoriasis or cannot discontinue phototherapy (Psoralen Ultraviolet A; Ultraviolet B).
  • Any uncontrolled significant medical condition.

About Pfizer

Pfizer Inc. is a global leader in biopharmaceutical innovation, dedicated to discovering, developing, and delivering advanced therapies that enhance patient outcomes across a wide range of medical conditions. With a rich history of scientific research and a commitment to quality, Pfizer focuses on areas such as oncology, immunology, cardiology, and rare diseases. The company leverages cutting-edge technology and collaborates with healthcare professionals, regulatory bodies, and academic institutions to conduct rigorous clinical trials that ensure the safety and efficacy of its products. Pfizer's mission is to bring breakthroughs that change patients' lives, exemplifying its commitment to health and wellness worldwide.

Locations

Durham, North Carolina, United States

Providence, Rhode Island, United States

Winston Salem, North Carolina, United States

Cincinnati, Ohio, United States

Springfield, Illinois, United States

Fridley, Minnesota, United States

Fresno, California, United States

Berlin, New Jersey, United States

Trumbull, Connecticut, United States

South Miami, Florida, United States

Cleveland, Ohio, United States

Hamilton, Ontario, Canada

Nashville, Tennessee, United States

High Point, North Carolina, United States

Springfield, Illinois, United States

Los Angeles, California, United States

Hellerup, , Denmark

Clarksburg, West Virginia, United States

Malvern East, Victoria, Australia

Orange Park, Florida, United States

Webster, Texas, United States

Vancouver, British Columbia, Canada

Montreal, Quebec, Canada

Miami, Florida, United States

Portland, Oregon, United States

Arlington Heights, Illinois, United States

Wilmington, North Carolina, United States

Windsor, Ontario, Canada

Greer, South Carolina, United States

Miami, Florida, United States

Louisville, Kentucky, United States

Evansville, Indiana, United States

Quebec, , Canada

Mobile, Alabama, United States

Haverhill, Massachusetts, United States

St. John's, Newfoundland And Labrador, Canada

Ormond Beach, Florida, United States

San Francisco, California, United States

Cincinnati, Ohio, United States

Trnava, , Slovakia

Winston Salem, North Carolina, United States

Longmont, Colorado, United States

Oceanside, California, United States

Manchester, , United Kingdom

Tucson, Arizona, United States

Wilmington, North Carolina, United States

Saint John's, Newfoundland And Labrador, Canada

Wilmington, North Carolina, United States

Winston Salem, North Carolina, United States

Greer, South Carolina, United States

Malvern, Victoria, Australia

Svendborg, , Denmark

Nuneaton, Warwickshire, United Kingdom

Fremont, California, United States

Los Angeles, California, United States

Louisville, Kentucky, United States

Louisville, Kentucky, United States

Beverly, Massachusetts, United States

Clinton Township, Michigan, United States

Wilmington, North Carolina, United States

Charleston, South Carolina, United States

Charleston, South Carolina, United States

Charleston, South Carolina, United States

San Antonio, Texas, United States

Ciudad Autonoma De Buenos Aires, C1114aap, Argentina

Ciudad Autonoma De Buenos Aires, , Argentina

Kogarah, New South Wales, Australia

Kogarah, New South Wales, Australia

Carlton, Victoria, Australia

Carlton, Victoria, Australia

Rio De Janeiro, Rj, Brazil

Sao Paulo, Sp, Brazil

Pleven, , Bulgaria

Sofia, , Bulgaria

Sofia, , Bulgaria

Sofia, , Bulgaria

Sofia, , Bulgaria

Vancouver, British Columbia, Canada

Aarhus C, , Denmark

Tampere, , Finland

Aathens, , Greece

Ioannina, , Greece

Thessaloniki, , Greece

Beek, , Netherlands

Bratislava, , Slovakia

London, Leytonstone, United Kingdom

Patients applied

0 patients applied

Trial Officials

Pfizer CT.gov Call Center

Study Director

Pfizer

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials